S J Luen, G Viale, S Nik-Zainal, P Savas, R Kammler, P Dell'Orto, O Biasi, A Degasperi, L C Brown, I Láng, G MacGrogan, C Tondini, M Bellet, F Villa, A Bernardo, E Ciruelos, P Karlsson, P Neven, M Climent, B Müller, W Joshum, H Bonnefoi, S Martino, N E Davidson, C Geyer, S K Chia, J N Ingle, R Coleman, C Solbach, B Thürlimann, M Colleoni, A S Coates, A Goldhirsch, G F Fleming, P A Francis, T P Speed, M M Regan, S Loi
BACKGROUND: Very young premenopausal women diagnosed with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. PATIENTS AND METHODS: Genomic sequencing was applied to HR+HER2- tumours from patients enrolled in the SOFT clinical trial to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1,276 patients (deep targeted sequencing, N=1258; whole-exome sequencing in a young-age, case-control subsample, N=82)...
January 25, 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology